E
Edward A. O'Neill
Researcher at Merck & Co.
Publications - 81
Citations - 4114
Edward A. O'Neill is an academic researcher from Merck & Co.. The author has contributed to research in topics: Sitagliptin & Placebo. The author has an hindex of 29, co-authored 80 publications receiving 3892 citations. Previous affiliations of Edward A. O'Neill include United States Military Academy.
Papers
More filters
Journal ArticleDOI
FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin.
Stephen J. O'Keefe,Jun'ichi Tamura,Jun'ichi Tamura,Randall L. Kincaid,Michael J. Tocci,Edward A. O'Neill +5 more
TL;DR: It is reported that transfection of a calcineurin catalytic subunit increases the 50% inhibitory concentration of the immunosuppressants FK-506 and CsA, and that a mutant subunit acts in synergy with phorbol ester alone to activate the interleukin-2 promoter in a drug-sensitive manner.
Journal ArticleDOI
Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B.
Betsy Frantz,E.C. Nordby,G D Bren,N. Steffan,C.V. Paya,R.L. Kincaid,Michael J. Tocci,Stephen J. O'Keefe,Edward A. O'Neill +8 more
TL;DR: These data provide the first demonstration in vivo thatactivation of a protein phosphatase can inactivate I kappa B, and suggest one possible explanation for mechanism‐based toxicities associated with FK‐506 and CsA by demonstrating that these drugs can inhibit the calcineurin‐dependent activation of a virtually ubiquitous transcription factor.
Journal ArticleDOI
Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Nigel J. Liverton,John W. Butcher,Christopher F. Claiborne,David A. Claremon,Brian E. Libby,Kevin Nguyen,Steven M. Pitzenberger,H. G. Selnick,Garry R. Smith,Andrew J. Tebben,Joe P. Vacca,Sandor L. Varga,Agarwal L,K B Dancheck,A J Forsyth,D S Fletcher,B. Frantz,W A Hanlon,C F Harper,S J Hofsess,M Kostura,Jiunn H. Lin,S Luell,Edward A. O'Neill,Stephen J. O'Keefe +24 more
TL;DR: 48, a potent and selective p38 MAP kinase inhibitor which inhibits lipopolysaccharide-stimulated release of TNF-alpha from human blood with an IC50 2.2 nM shows good oral bioavailability in rat and rhesus monkey, and demonstrates significant improvement in measures of disease progression in a rat adjuvant-induced arthritis model.
Journal ArticleDOI
The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding.
Betsy Frantz,Tracey Klatt,Margaret Pang,Janey N. Parsons,Anna M. Rolando,Hollis R. Williams,Michael J. Tocci,Stephen J. O'Keefe,Edward A. O'Neill +8 more
TL;DR: It is demonstrated in vivo that at concentrations consistent with its IC50 as a cytokine inhibitor, SB203580 can inhibit stimulus-induced phosphorylation of p38 at the Thr-Gly-Tyr activation motif.
Journal ArticleDOI
Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes
Cynthia J. Girman,Tzuyung D. Kou,Bing Cai,Charles M. Alexander,Edward A. O'Neill,D. E. Williams-Herman,L. Katz +6 more
TL;DR: The aetiology of acute pancreatitis is complex, and many risk factors for AP are shared by patients with type 2 diabetes mellitus (T2DM), but few have assessed risk Factors for AP specifically in T2DM patients.